4//SEC Filing
Pagano Russell P. 4
Accession 0001209191-13-014349
CIK 0001138400other
Filed
Mar 4, 7:00 PM ET
Accepted
Mar 5, 7:46 PM ET
Size
25.9 KB
Accession
0001209191-13-014349
Insider Transaction Report
Form 4
Pagano Russell P.
VP, Reg. & Clinical Affairs
Transactions
- Disposition to Issuer
Stock Options (right to buy)
2013-03-01−35,000→ 0 totalExercise: $11.97Exp: 2020-02-03→ Common Stock (35,000 underlying) - Tax Payment
Common Stock
2013-03-01$9.07/sh−32,305$293,129→ 44,411 total - Exercise/Conversion
Stock Options (right to buy)
2013-03-01−70,000→ 0 totalExercise: $2.08Exp: 2022-02-28→ Common Stock (70,000 underlying) - Disposition to Issuer
Stock Options (right to buy)
2013-03-01−10,000→ 0 totalExercise: $14.41Exp: 2018-02-07→ Common Stock (10,000 underlying) - Disposition to Issuer
Stock Options (right to buy)
2013-03-01−35,000→ 0 totalExercise: $8.54Exp: 2019-02-26→ Common Stock (35,000 underlying) - Exercise/Conversion
Common Stock
2013-03-01$2.08/sh+70,000$145,600→ 76,716 total - Disposition to Issuer
Common Stock
2013-03-01−44,411→ 0 total - Disposition to Issuer
Stock Options (right to buy)
2013-03-01−35,000→ 0 totalExercise: $13.45Exp: 2021-01-19→ Common Stock (35,000 underlying) - Disposition to Issuer
Stock Options (right to buy)
2013-03-01−25,000→ 0 totalExercise: $9.70Exp: 2020-09-02→ Common Stock (25,000 underlying)
Footnotes (7)
- [F1]This transaction represents a withholding of shares to cover the payment of exercise price and federal tax liability pursuant to an exercise of non-qualified stock options.
- [F2]Disposed of pursuant to the Agreement and Plan of Merger ("Merger Agreement") dated as of November 19, 2012, by and among the Company, Wright Medical Group, Inc. ("Wright"), Achilles Merger Subsidiary, Inc. and Achilles Acquisition Subsidiary, LLC in exchange for the following merger consideration per share of the Company's common stock: (a) $1.50 in cash, without interest; (b) 0.2482 of a share of Wright's common stock; and (c) one contingent value right ("CVR") issued by Wright.
- [F3]Option exercised. Pursuant to the Merger Agreement, this stock option was conditionally vested to 100% subject to exercise upon the merger transaction. The reporting person received merger consideration described in footnote (2) above.
- [F4]Option canceled. Pursuant to the Merger Agreement, the reporting person entered into an agreement with the issuer to terminate stock options with an exercise price greater than $13.00.
- [F5]Pursuant to the Merger Agreement, the stock options granted by the issuer converted into options to purchase 18,263 shares of Wright common stock at an exercise price of $16.37 per share.
- [F6]Pursuant to the Merger Agreement with Wright, the stock options granted by the issuer converted into options to purchase 18,263 shares of Wright common stock at an exercise price of $22.94 per share.
- [F7]Pursuant to the Merger Agreement, the stock options granted by the issuer converted into options to purchase 13,045 shares of Wright common stock at an exercise price of $18.59 per share.
Issuer
BIOMIMETIC THERAPEUTICS, INC.
CIK 0001138400
Entity typeother
Related Parties
1- filerCIK 0001428107
Filing Metadata
- Form type
- 4
- Filed
- Mar 4, 7:00 PM ET
- Accepted
- Mar 5, 7:46 PM ET
- Size
- 25.9 KB